MedPath

Estrella Biopharma, Inc.

Estrella Biopharma, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2022-01-01
Employees
11
Market Cap
-
Website
http://www.estrellabio.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1
Recruiting
Conditions
Lymphoma, Non-Hodgkins
Lymphomas Non-Hodgkin's B-Cell
Large B-Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma
B-Cell Non-Hodgkin's Lymphoma (NHL)
Lymphoma, Non-Hodgkin
CNS Lymphoma
Non-Hodgkin Lymphoma
Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
First Posted Date
2024-04-02
Last Posted Date
2024-08-02
Lead Sponsor
Estrella Biopharma, Inc.
Target Recruit Count
21
Registration Number
NCT06343311
Locations
🇺🇸

University of California, Davis, Sacramento, California, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath